Display options
Cite
Suzuki R, Takagi T, Hikichi T, et al. Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer. Oncol Lett. 2016;11(5):3441-3445doi: 10.3892/ol.2016.4381.
Suzuki, R., Takagi, T., Hikichi, T., Konno, N., Sugimoto, M., Watanabe, K. O., Nakamura, J., Waragai, Y., Kikuchi, H., Takasumi, M., Watanabe, H., & Ohira, H. (2016). Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer. Oncology letters, 11(5), 3441-3445. https://doi.org/10.3892/ol.2016.4381
Suzuki, Rei, et al. "Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer." Oncology letters vol. 11,5 (2016): 3441-3445. doi: https://doi.org/10.3892/ol.2016.4381
Suzuki R, Takagi T, Hikichi T, Konno N, Sugimoto M, Watanabe KO, Nakamura J, Waragai Y, Kikuchi H, Takasumi M, Watanabe H, Ohira H. Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer. Oncol Lett. 2016 May;11(5):3441-3445. doi: 10.3892/ol.2016.4381. Epub 2016 Mar 29. PMID: 27123132; PMCID: PMC4840986.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2016 May;11(5):3441-3445. doi: 10.3892/ol.2016.4381. Epub 2016 Mar 29.

Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer.

Oncology letters

Rei Suzuki, Tadayuki Takagi, Takuto Hikichi, Naoki Konno, Mitsuru Sugimoto, K O Watanabe, Jun Nakamura, Yuichi Waragai, Hitomi Kikuchi, Mika Takasumi, Hiroshi Watanabe, Hiromasa Ohira

Affiliations

  1. Department of Gastroenterology and Rheumatology, School of Medicine, Fukushima Medical University, Fukushima 960-1295, Japan.
  2. Department of Endoscopy, School of Medicine, Fukushima Medical University, Fukushima 960-1295, Japan.

PMID: 27123132 PMCID: PMC4840986 DOI: 10.3892/ol.2016.4381

Abstract

As gemcitabine is a key anti-tumor agent for unresectable pancreatic ductal adenocarcinoma (PDAC), it is important to predict the outcomes of gemcitabine chemotherapy. The present study aimed to confirm whether the derived neutrophil-to-lymphocyte ratio (dNLR) is able to predict chemotherapy outcomes. To elucidate the role of dNLR in patients that underwent chemotherapy, the current study evaluated clinicopathological variables in 31 patients with unresectable PDAC treated with gemcitabine. The correlation between clinicopathological variables, and progression-free survival (PFS) and overall survival (OS) time were investigated. Univariate analysis revealed that there were no significant differences in PFS and OS as a function of age (<65 vs. ≥65 years), gender, tumor location (pancreas head vs. body/tail), tumor diameter (<23 vs. ≥23 mm) or serum carbohydrate antigen 19-9 concentration level (<3,800 vs. ≥3,800 U/ml). However, disease stage (locally advanced vs. metastatic) and the dNLR (<2.5 vs. ≥2.5) significantly affected PFS and OS. Multivariate analysis subsequently revealed that a dNLR of ≥2.5 was an independent prognostic factor for poor PFS (P=0.003) and OS (P=0.026). In conclusion, data from the present study suggests that the pre-treatment dNLR is an independent prognostic factor to predict PFS and OS in patients with unresectable PDAC treated with gemcitabine. This indicates that dNLR has a potential role in stratifying patients that may benefit from gemcitabine therapy.

Keywords: chemotherapy; lymphocyte; marker; neutrophil; pancreatic carcinoma

References

  1. Br J Cancer. 2007 Feb 12;96(3):457-63 - PubMed
  2. Br J Cancer. 2012 Aug 7;107(4):695-9 - PubMed
  3. Anticancer Res. 2013 Oct;33(10):4591-4 - PubMed
  4. Br J Cancer. 2013 Apr 16;108(7):1488-94 - PubMed
  5. Cancer Cell. 2011 Apr 12;19(4):456-69 - PubMed
  6. N Engl J Med. 2011 May 12;364(19):1817-25 - PubMed
  7. Br J Cancer. 2013 May 28;108(10):2063-9 - PubMed
  8. J Exp Clin Cancer Res. 2009 Jun 16;28:83 - PubMed
  9. J Natl Cancer Inst. 2015 Jan 31;107(2):null - PubMed
  10. N Engl J Med. 2013 Oct 31;369(18):1691-703 - PubMed
  11. Surgery. 2013 Apr;153(4):565-75 - PubMed
  12. Br J Cancer. 2011 Apr 12;104(8):1288-95 - PubMed
  13. Ann Surg. 2004 Jun;239(6):763-9; discussion 769-71 - PubMed
  14. Intern Med J. 2014 Jul;44(7):676-82 - PubMed
  15. Oncology. 2007;73(3-4):215-20 - PubMed
  16. PLoS One. 2013 Nov 04;8(11):e78225 - PubMed
  17. J Cancer Res Clin Oncol. 2013 Apr;139(4):681-9 - PubMed
  18. BMC Cancer. 2013 Jul 22;13:350 - PubMed
  19. J Am Coll Surg. 1999 Jul;189(1):1-7 - PubMed
  20. Cancer Res. 2003 May 15;63(10):2649-57 - PubMed
  21. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 - PubMed
  22. J Natl Cancer Inst. 2014 Jan;106(1):djt347 - PubMed
  23. Gastroenterology. 2009 Jan;136(1):187-95 - PubMed
  24. Br J Cancer. 2013 Jul 23;109(2):395-400 - PubMed

Publication Types